Search Press releases Keywords From To Category Therapy AreasAxial spondyloarthritisChronic inflammatory demyelinating polyneuropathyCrohn's diseaseEpilepsyHidradenitis suppurativaImmune ThrombocytopeniaImmune-mediated necrotizing myopathyLupusMyasthenia gravisOsteoporosisParkinson's diseaseProgressive supranuclear palsyPsoriasisPsoriatic arthritisRestless legs syndromeRheumatoid Arthritis TopicCorporateFinancialsPartnershipsPipeline progressResearch UCB MedicinesbimekizumabBriviactCimziaEvenityNayzilamNeuproVimpat 1 Apr 2003 Data analysis shows Keppra® reduced partial seizures in nearly 80 percent of elderly patients in a community-based trial. Read More 14 Mar 2003 UCB Group : confirmation of an increase in ordinary profits of 7%. Read More 26 Feb 2003 Celltech Group PLC (CCH) - Offer for Oxford GlycoScience Read More 6 Feb 2003 The UCB Group in 2002: Preliminary Unaudited Profits. Record Ordinary Profits before Tax of € 494 million, an increase of 7% Read More 31 Jan 2003 UCB closes on its acquisition of Solutia's Resins, Additives and Adhesives businesses Read More 22 Jan 2003 UCB : Fourth quarter year-to-date Zyrtec sales in the US increase by 13%. Read More Pagination First page Previous page Previous … Page 187 Page 188 Page 189 Page 190 Page 191 Page 192 Page 193 Current page 194 Page 195 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
